Cruden N - Search Results

1

Clinical outcomes following balloon aortic valvuloplasty.

Bularga A, Bing R, Shah AS, Adamson PD, Behan M, Newby DE, Flapan A, Uren N, Cruden N. Bularga A, et al. Among authors: cruden n. Open Heart. 2020 Sep;7(2):e001330. doi: 10.1136/openhrt-2020-001330. Open Heart. 2020. PMID: 32907920 Free PMC article.

2

Effect of cold exposure, exercise and high altitude on plasma endothelin-1 and endothelial cell markers in man.

Cruden NL, Newby DE, Ross JA, Johnston NR, Webb DJ. Cruden NL, et al. Scott Med J. 1999 Oct;44(5):143-6. doi: 10.1177/003693309904400506. Scott Med J. 1999. PMID: 10629910

3

Salmeterol for the prevention of high-altitude pulmonary edema.

Cruden NL, Newby DE, Webb DJ. Cruden NL, et al. N Engl J Med. 2002 Oct 17;347(16):1282-5; author reply 1282-5. doi: 10.1056/NEJM200210173471618. N Engl J Med. 2002. PMID: 12393831 Free article. No abstract available.

4

Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers.

Harding SA, Sarma J, Josephs DH, Cruden NL, Din JN, Twomey PJ, Fox KA, Newby DE. Harding SA, et al. Among authors: cruden nl. Circulation. 2004 Apr 27;109(16):1926-9. doi: 10.1161/01.CIR.0000127128.52679.E4. Epub 2004 Apr 12. Circulation. 2004. PMID: 15078798

5

Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.

Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Cruden NL, et al. Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1043-8. doi: 10.1161/01.ATV.0000129331.21092.1d. Epub 2004 Apr 22. Arterioscler Thromb Vasc Biol. 2004. PMID: 15105283 Clinical Trial.

6

Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.

Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Cruden NL, et al. Hypertension. 2004 Dec;44(6):913-8. doi: 10.1161/01.HYP.0000146483.78994.56. Epub 2004 Oct 18. Hypertension. 2004. PMID: 15492133 Clinical Trial.

7

Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?

Cruden NL, Newby DE. Cruden NL, et al. Am J Cardiovasc Drugs. 2004;4(6):345-53. doi: 10.2165/00129784-200404060-00002. Am J Cardiovasc Drugs. 2004. PMID: 15554719 Review.

8

B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.

Cruden NL, Tse GH, Fox KA, Ludlam CA, Megson I, Newby DE. Cruden NL, et al. Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):772-7. doi: 10.1161/01.ATV.0000157157.78822.25. Epub 2005 Jan 27. Arterioscler Thromb Vasc Biol. 2005. PMID: 15681300 Clinical Trial.

9

Clots, kinins and coronaries.

Cruden NL, Newby DE. Cruden NL, et al. Atherosclerosis. 2005 Dec;183(2):189-98. doi: 10.1016/j.atherosclerosis.2005.05.038. Epub 2005 Jul 14. Atherosclerosis. 2005. PMID: 16023651 Review.

10

Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.

Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE. Cruden NL, et al. Thromb Res. 2006;118(2):189-97. doi: 10.1016/j.thromres.2005.06.014. Epub 2005 Aug 1. Thromb Res. 2006. PMID: 16055173

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters